Resistance to Tnf-A and Adriamycin in the Human Breast Cancer Mcf-7 Cell Line: Relationship To Mdr1, Mnsod, and Tnf Gene Expression

Cancer Research

Volumn 54, Issue 3, 1994, Pages 825-831

  Benard, Jean ^c   Tursz, Thomas ^a   Chouaib, Salem ^a  

^a Laboratory of Immunology ^*  (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Laboratory of Clinical and Molecular Pharmacology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MANGANESE DERIVATIVE; MONOCLONAL ANTIBODY; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR;

ARTICLE; BREAST ADENOCARCINOMA; CANCER CHEMOTHERAPY; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NORTHERN BLOTTING; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; BREAST NEOPLASMS; CARRIER PROTEINS; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INDUCTION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; HUMANS; MEMBRANE GLYCOPROTEINS; P-GLYCOPROTEIN; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; SIGNAL TRANSDUCTION; SUPEROXIDE DISMUTASE; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0028175470     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Carswell, E.A., Old, L.J., Kassel, R.L., Fiore, N., and Williamson, B. An endotoxin-induced serum that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA, 72: 366-3670, 1975.
2. Havell, E.A., Fiers, W., and North, N.J. The antitumor function of TNF.J. Exp. Med., 767: 1067-1085, 1988.
3. Williamson, B.D., Carswell, E.A., Rubin, B.Y., Prendergast, Y.S., and Old, L.J. Human tumor necrosis factor produced by B-cell lines: synergistic cytotoxic interaction with human interferon. Proc. Natl. Acad. Sci. USA, 82: 7626-7630, 1985.
4. Sugurman, B.J., Aggarwal, P.E., Hass, T.E., Figari, I.S., and Paladino, M.A. Recombinant human tumor necrosis factor: effects on proliferation of normal and transformed cells. Science (Washington DC), 230: 943-945, 1985.
5. Blay, Y., Bertoglio, J., Fradelizi, D., and Chouaib, S. Functional interaction between IL-2 and TNF in the differentiation of LGL into LAK effectors. Int. J. Cancer, 44: 598-604, 1989.
6. Chouaib, S., Bertoglio, J., Blay, J.Y., Marchiol, F.C., and Fradelizi, D. Generation of lymphokine-activated killer cells: synergy between tumor necrosis factor and Interleukin-2. Proc. Natl. Acad. Sci. USA, 85: 6875-6879, 1988.
7. Robinet, E., Branellec, D., Blay, J.Y., Gay, F., and Chouaib, S. Evidence for tumor necrosis factor a involvement in the optimal induction of class-I allospeciflc cytotoxic T cells. J. Immunol., 144: 4555-4561, 1990.
8. Chouaib, S., Branellec, D., and Buurman, W.A. More insights into the complex physiology of TNF. Immunol. Today, 12: 141-142, 1991.
9. Imamura, K., Spriggs, D.R., and Kufe, D.W. Expression of tumor necrosis factor receptors and internalization of receptor-bound ligand. J. Immunol., 139: 3989-2992, 1987.
10. Ishikura, H., Hon, K., and Bloch, A. Differential biological effects resulting from biomodal binding of recombinant human tumor necrosis factor to myeloid leukemia cells. Blood, 72: 419-429, 1989.
11. Tsujimoto, M., Yip, K., and Vilcek, J. Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells. Proc. Natl. Acad. Sci. USA, 82: 7626-7630, 1985.
12. Branellec, D., Mishal, Z., and Chouaib, S. Modulation of TNF-mediated cell lysis in vitro: further analysis of intracellular signaling. Immnopharmacol., 26: 147-156, 1993.
13. Chouaib, S., Robinet, E., Zyad, A., and Branellec, D. The tumor necrosis factor a: pleiotropic cytokine. Bull. Cancer, 79: 935-949, 1992.
14. Wong, G.H., and Goeddel, D.V. Induction of superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science (Washington DC), 242: 941-944, 1988.
15. Wong, C.H.W., Elwell, J.H., Oberley, L.W., and Goeddel, D.V. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell, 58: 923-931, 1989.
16. Fruehauf, J.P., Mimnaugh, E.G., and Sinha, B.K. Doxorubicin-induced cross-resistance to tumor necrosis factor (TNF) related to differential processing. J. Immunother., 10: 165-173, 1991.
17. Vanhaesebroeck, B., Decoster, E., Van Ostade, X., Van Bladel, S., Lenaerts, A., Van Roy, F., and Fiers, W. Expression of an exogenous tumor necrosis factor (TNF) gene in TNF-sensitive cell lines confers resistance to TNF-mediated cell lysis. J. Immunol., 148: 2785-2794, 1992.
18. Himeno, T., Watanabe, N., Yauchi, N., Maeda, M., Tsuji, Y., Okamoto, H., and Niitsu, Y. Expression of endogenous TNF as a protective protein against the cytotoxicity of exogenous TNF. Cancer Res., 50: 4941-945, 1990.
19. Okamoto, T., Watanabe, N., Yamauchi, N., Tsuji, Y., Tsuji, N., Itoh, Y., Neda, H., and Niitsu, Y. Endogenous tumor necrosis factor exerts its protective function intracellularly against the cytotoxicity of exogenous tumor necrosis factor. Cancer Res., 52: 5278-5281, 1992.
20. Riordan, J.R., and Ling, V. Genetic and biomedical characterization of multidrug resistance. Pharmacol. Ther., 28: 51-75, 1985.
21. Fojo, A., Cornwell, M., Cardarelli, C., Clark, D.P., Richert, N., Shen, D., Ueda, K., Willingham, M., Gottesman, M., and Pastan I. Molecular biology of drug resistance. Breast Cancer Res., 9: 5-16, 1987.
22. Gerlach, J., Kartner, N., Bell, D., and Ling, V. Multidrug resistance. Cancer Surv., 5: 25-46, 1986.
23. Pastan, I., and Gottesman, M. Multidrug resistance in human cancer. N. Engl. J. Med., 316: 1388-1393, 1987.
24. Ling, V., Kartner, N., Sudo, T., Siminovitch, L., and Riordan, J.R. Multidrug resistance phenotype in Chinese hamster ovary cells. Cancer Treat. Rep., 67: 869-874, 1983.
25. Bourhis, J., Goldstein, L., Riou, G., Pastan, I., Gottesman, M., and Benard, J. Expression of multidrug resistance gene in ovarian carcinomas. Cancer Res., 49: 5062-5065, 1989.
26. Benard, J., Da Silva, J., Teyssier, J.R., and Riou, G. Overexpression of MDR1 gene with no DNA amplification in a multiple drug resistance human ovarian cancer line. Int. J. Cancer, 43: 471-77, 1989.
27. Ofer, K., Jaroszewski, J.W., Clarke, R., Fairchild, C.R., Schoenlein, P., Goldeberg, S., Gottesman, M., and Cohen, J.S. The multidrug resistance phenotype: 31P nuclear magnetic resonance characterization and 2-desoxyglucose toxicity. Cancer Res., 51: 1638-1644, 1991.
28. Blick, M., Sherwin, S.A., Rosenblum, M., and Gutterman, J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res., 47: 2986-2989, 1987.
29. Feinberg, B., Kurzrock, R., Talpaz, M., Blick, M., Saks, S., and Gutterman, J.U. A phase I trial of intravenously administered recombinant tumor necrosis factor a in cancer patients. J. Clin. Oncol., 6: 1328-1334, 1988.
30. Hofsli, E., and Nissen-Meyer, J. Reversal of drug resistance by erythromycin: erythromycin increases the accumulation of actinomycin D and doxorubicin in multidrug resistant cells. Int. J. Cancer, 44: 149-154, 1989.
31. Hofsli, E., and Nissen-Meyer, J. Effect of erythromycin and tumor necrosis factor on the drug resistance of multi-drug-resistant cells: reversal of drug-resitance by erythromycin. Int. J. Cancer, 43: 224-226, 1989.
32. Salmon, S.E., Soehnlen, B., Dalton, W.S., Meltzer, P., and Scuderi, P. Effect of tumor necrosis factor on sensitive and multidrug resistant human leukemia and myeloma cell line. Blood, 74: 1723-1727, 1989.
33. Hong, W.S., Sijo, N., Sasaki, Y., Shinkai, T., Eguchi, K., Sacurai, M., Takamashi, H., Nakano, H., Nakagawa, K., and Twentyman, P. In vitro growth inhibition of cis-platin resistant human lung cancer cell lines by recombinant human tumor necrosis factor and/or recombinant human interferon-? by virtue of collateral sensitivity. Jpn. J. Cancer Res. (Gann), 78: 1274-1280, 1986.
34. Ujhazy, P., Chen, Y., Fredericks, W., and Ehrke, M. Collateral sensitivity to tumor necrosis factor in an Adriamycin-resistant EL4 cell line. Proc. Am. Assoc. Cancer. Res., 30: 409-414, 1987.
35. Hofsli, E., and Nissen-Meyer, J. Tumor necrosis factor (TNF) and its effect on multidrug resistant (MDR) cells. Lymphokine Res., 7: 299-304, 1988.
36. Dollbaum, C., Creasey, A., Dairkee, S.H., Hiller, A., Rudolph, A., Lin, L., Vitt, C., Smith, H. Specificity of tumor necrosis factor toxicity for human mammary carcinomas relative to normal mammary epithelium and correlation with response to doxorubicin. Proc. Natl. Acad. Sci. USA, 85: 4740-4755, 1988.
37. Wright, S., and Tam, A. U937 tumor cell variants selected for resistance to lysis by TNF are also resistant to lysis by chemotherapeutic cytotoxic drugs. In: S. Karger, A.G. Basel, B. Bonavida, G. Granger (eds.), Second International Conference on Tumor Necrosis Factor and Related Cytokines, p. 41. Napa, CA: 1989.
38. Neale, M.L., and Matthews, N. Development of tumor cell resistance to tumor necrosis factor does not confer resistance to cytotoxic drugs. Eur. J. Cancer Clin. Oncol., 25: 133-137, 1989.
39. Fairchild, C.R., Ivy, S.P., Kao-Shang, C.S., Whang-Peng, J., Rosen, N., Israel, M.A., Melera, P.W., Cowan, K.H., and Goldsmith, L. Isolation of amplified and overexpressed DNA sequences from Adriamycin-resistant human breast cancer cells. Cancer Res., 47: 5141-5148, 1987.
40. Clarke, R., Currier, S., Kaplan, O., Lovelace, E., Boulay, V., Gottesman, M.M., and Dicson, R.B. Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. J. Natl. Cancer Inst., 84: 1506-1512, 1992.
41. Zyad, A., Branellec, D., Mahe\ Y., Tursz, T., and Chouaib, S. The development of human tumor cell-resistance to tumor necrosis factor-a does not confer resistance to cytokine-induced cellular cytotoxic mechanisms. Int. J. Cancer, 52: 953-958, 1992.
42. Kartner, N., Evenden-Porelle, D., Bradley, G., and Ling, V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature (Lond.), 316: 820-822, 1985.
43. Dignam, J.D., Lebovitz, R.M., and Roeder, R.G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res., 11: 1475-1489, 1983.
44. Feuillard, J., Gouy, H., Bismutch, G., Lee, L.M., Debre\ P., and Korner, M. NF-kB activation by tumor necrosi factor a in the Jurkat T cell line is independent of protein kinase A., protein kinase C and Ca2+-regulated kinases. Cytokine, 3: 1-9, 1991.
45. Scheper, R.J., Dalton, W.S., Grogan, T.M., Schlosser, A., Bellamy, W.T., Taylor, C.W., Scderi, P., and Spier, C. Altered expression of P-glycoprotein and cellular adhesion molecules on human multi-drug-resistant tumor cells does not affect their susceptibility to NK- and LAK-mediated cytotoxicity. Int. J. Cancer, 48: 562-567, 1991.
46. Bradley, G., Juranka, P.F., and Ling, V. Mechanism of multidrug-resistance. Biophys. Biochem. Acta, 948: 87-128, 1988.
47. Spriggs, D.R., and Yates, S.W. Cancer chemotherapy. Experiences with TNF administration in humans. In: B. Beutler (ed.), Tumor Necrosis Factors: the Molecules and Their Emerging Role in Medicine, pp. 383-406. New York: Raven Press, Ltd., 1992.
48. Alexander, R.B., Nelson, W.G., and Coffey, D.S. Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from therapeutic drugs targeted at DNA topoisomerase II. Cancer Res., 47: 2403-2406, 1987.
49. Orr, D., Oldham, R., Lewis, M., Bertoli, L., and Birch, R. Phase I study of the sequenced administration of etoposide and recombinant tumor necrosis factor in patients with advanced malignancy. Proc. Am. Soc. Clin. Oncol., 8: 741-745, 1989.
50. Dallbaum, C., Creasey, A.A., and Dairkee, S.H. Specificity of tumor necrosis factor toxicity for human mammary carcinoma relative to normal mammary epithelium and correlation with response to doxorubicin. Proc. Natl. Acad. Sci. USA, 85: 4740-4744, 1988.
51. Lowenthal, J.W., Ballard, D.W., Bohnlein, E., and Greene, W.C. Tumor necrosis factor a induces proteins that bind to kB-like enhancer element and regulate Interleukin-2 receptor a chain gene expression in primary human T lymphocytes. Proc. Natl. Acad. Sci. USA, 86: 2331-2335, 1989.
52. Zhang, Y., Lin, J., and Vilcek, J. Interleukin-6 induction by tumor necrosis factor and interleukin-1 in human fibroblasts involves activation of nuclear factor binding to a kB-like sequence. Mol. Cell. Biol., 10: 818-3823, 1989.
53. Pessara, U., and Koch, N. Tumor necrosis factor a regulates expression of the major histocompatibility complex class II-associated invariant chain by binding of an NF-kB-like factor to a promoter element. Mol. Cell. Biol., 10: 4146-4154, 1990.
54. Wright, S.C., Tarn, A.W., and Kumar, P. Selection of tumor cell variants for resistance to tumor necrosis factor also induces a form of pleiotropic drug resistance. Cancer Immunol. Immunother. 34: 399-406, 1992.
55. Sinha, B., and Mimnaugh, E. Free radicals and anticancer drug resistance: oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumors. Free Radical Biol. Med., 8: 567-558, 1990.
56. Batist, G., Tulpule, A., Sinha, B., Katki, A., Meyer, C., and Cowan, K. Overexpression of a novel anionic glutathione transferase in multidrug resistant human breast cancer cells. J. Biol. Chem., 261: 15544-15549, 1986.
57. Yamauchi, N., Kuriyama, H., Watanabe, N., Neda, H., Maeda, M., and Niitsu, Y Intracellular hydroxyl radical production induced by recombinant human tumor necrosis factor and its implication in the killing of tumor cells in vitro. Cancer Res., 49: 1671-1675, 1989.
58. Matthews, N., Neale, M., Jackson, S., and Stark, J. Tumor cell killing by tumor necrosis factor: inhibition by anaerobic conditions, free radical scavengers and inhibitors of arachidonate metabolism. Immunology, 62: 153-155, 1987.
59. Bagglioni, C. Mechanisms of cytotoxicity, cytolysis, and growth stimulation by TNF. In: B. Beutler (ed.), Tumor Necrosis Factors: the Molecules and Their Emerging Role in Medicine, pp. 425-437, New York: Raven Press, Ltd., 1992.